AYTU - Aytu BioScience, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.45
-0.34 (-12.19%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.79
Open2.80
Bid2.26 x 700
Ask2.75 x 400
Day's Range2.45 - 6.15
52 Week Range2.21 - 25.20
Volume1,706,316
Avg. Volume42,776
Market Cap11.999M
Beta1.39
PE Ratio (TTM)N/A
EPS (TTM)-20.85
Earnings DateFeb 7, 2018 - Feb 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.00
Trade prices are not sourced from all markets
  • Aytu BioScience Inc (AYTU): Has Recent Earnings Growth Beaten Long-Term Trend?
    Simply Wall St.18 days ago

    Aytu BioScience Inc (AYTU): Has Recent Earnings Growth Beaten Long-Term Trend?

    Measuring Aytu BioScience Inc’s (NASDAQ:AYTU) track record of past performance is a useful exercise for investors. It enables us to understand whether or not the company has met or exceedRead More...

  • ACCESSWIRE19 days ago

    Aytu BioScience, Inc. to Present at the 10th Annual LD Micro Main Event

    LOS ANGELES, CA / ACCESSWIRE / November 29, 201 7 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, ...

  • Aytu BioScience, Inc. :AYTU-US: Earnings Analysis: Q1, 2018 By the Numbers : November 28, 2017
    Capital Cube20 days ago

    Aytu BioScience, Inc. :AYTU-US: Earnings Analysis: Q1, 2018 By the Numbers : November 28, 2017

    Categories: Yahoo FinanceGet free summary analysis Aytu BioScience, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Aytu BioScience, Inc. – Career Education Corporation, Capella Education Company and Cambium Learning Group, Inc. (CECO-US, CPLA-US and ABCD-US) that have also reported for this period. Highlights Summary ... Read more (Read more...)

  • Aytu BioScience Provides Update on the Continued Growth of Natesto® in the U.S.
    PR Newswire20 days ago

    Aytu BioScience Provides Update on the Continued Growth of Natesto® in the U.S.

    ENGLEWOOD, Colo., Nov. 28, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today provided an update on the launch of Natesto in the U.S.  Significant Natesto prescription growth continued through October 2017, with prescriptions increasing 17% from the previous month, reaching their highest levels to date.  Additionally, in October, the number of physicians prescribing Natesto increased 16% from the previous month.

  • Aytu BioScience Provides Fiscal First Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET
    PR Newswirelast month

    Aytu BioScience Provides Fiscal First Quarter 2018 Business Update - Live Conference Call and Webcast Today at 4:30 pm ET

    ENGLEWOOD, Colo. , Nov. 9, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today ...

  • Aytu BioScience Receives Market Approval from the Australian Therapeutic Goods Administration for the MiOXSYS® System for Male Infertility
    PR Newswirelast month

    Aytu BioScience Receives Market Approval from the Australian Therapeutic Goods Administration for the MiOXSYS® System for Male Infertility

    ENGLEWOOD, Colo., Nov. 7, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that the Australian Government Department of Health and Therapeutic Goods Administration (TGA) has approved the MiOXSYS® System for inclusion on the Australian Register of Therapeutic Goods. Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, "MiOXSYS continues to gain traction with its international commercial expansion as regulatory bodies, like Australia's TGA, approve the product for clinical use in the assessment of male infertility. In Australia, approximately one in six couples suffer from infertility, and almost half of these cases can be attributed to male factor infertility.

  • Aytu BioScience to Report Fiscal First Quarter 2018 Results and Business Update
    PR Newswire2 months ago

    Aytu BioScience to Report Fiscal First Quarter 2018 Results and Business Update

    ENGLEWOOD, Colo., Nov. 2, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that the Company will present its operational results for the fiscal first quarter 2018 on Thursday, November 9, 2017, at 4:30 p.m. ET.  The Company will review recent accomplishments and provide an overview of its business and growth strategy. The webcast will be accessible live and archived on Aytu BioScience's website, within the Investors section under Corporate Presentations & Media, at aytubio.com, for 90 days. Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health.

  • Aytu BioScience Presents Clinical Findings for its MiOXSYS® System at 73rd Annual Meeting of the American Society of Reproductive Medicine
    PR Newswire2 months ago

    Aytu BioScience Presents Clinical Findings for its MiOXSYS® System at 73rd Annual Meeting of the American Society of Reproductive Medicine

    ENGLEWOOD, Colo. , Nov. 1, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today ...

  • Aytu BioScience Provides Quarterly Update on the Natesto® U.S. Launch
    PR Newswire2 months ago

    Aytu BioScience Provides Quarterly Update on the Natesto® U.S. Launch

    ENGLEWOOD, Colo. , Oct. 26, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today ...

  • GlobeNewswire2 months ago

    Aytu BioScience, Inc. (Nasdaq: AYTU) to Ring The Nasdaq Stock Market Closing Bell

    What: Aytu BioScience, Inc., a specialty life sciences company focused on global commercialization of novel products in the field of urology, will visit the Nasdaq MarketSite in Times Square. In honor ...

  • Aytu BioScience to Ring The NASDAQ Closing Bell Friday, October 20, 2017
    PR Newswire2 months ago

    Aytu BioScience to Ring The NASDAQ Closing Bell Friday, October 20, 2017

    ENGLEWOOD, Colo., Oct. 19, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that the Company will ring the NASDAQ closing bell on Friday, October 20, 2017 at 4:00 p.m. EDT. The bell ringing will celebrate the Company's recent accomplishments and listing on The NASDAQ Capital Market. The Company was approved for listing and begins trading on The NASDAQ Capital Market on Friday, October 20th under the company's current ticker symbol, AYTU.

  • Aytu BioScience Announces Uplisting to The NASDAQ Capital Market
    PR Newswire2 months ago

    Aytu BioScience Announces Uplisting to The NASDAQ Capital Market

    ENGLEWOOD, Colo. , Oct. 18, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today ...

  • CNW Group2 months ago

    Aytu BioScience Corporate Presentation is Now Available for On-Demand Viewing

    Aytu BioScience Corporate Presentation is Now Available for On-Demand Viewing

  • PR Newswire2 months ago

    Aytu BioScience Corporate Presentation is Now Available for On-Demand Viewing

    Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation ENGLEWOOD, Colo. , Oct. 9, 2017 /PRNewswire/ --  Aytu BioScience ...

  • Aytu BioScience Announces International Distribution Agreement for Fiera® in Japan
    PR Newswire2 months ago

    Aytu BioScience Announces International Distribution Agreement for Fiera® in Japan

    ENGLEWOOD, Colo., Oct. 3, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that the company has entered into a distribution agreement with Mitsuboshi Product Planning Ltd to market and distribute Fiera in Japan.  Mitsuboshi is a specialty life sciences company engaged in the research, development and commercialization of products related to infertility and female sexual wellness.  Mitsuboshi is the company's first international distributor of Fiera, and the company expects to announce additional international distribution partnerships for Fiera in the future. Up to 9 million Japanese women express one or more sexual concerns.  The Japanese sexual wellness market has been estimated at over $270 million annually.

  • Aytu BioScience, Inc. :AYTU-US: Earnings Analysis: Q4, 2017 By the Numbers : September 29, 2017
    Capital Cube3 months ago

    Aytu BioScience, Inc. :AYTU-US: Earnings Analysis: Q4, 2017 By the Numbers : September 29, 2017

    Categories: Yahoo FinanceGet free summary analysis Aytu BioScience, Inc. reports financial results for the quarter ended June 30, 2017. Highlights Summary numbers: Revenues of USD 0.84 million, Net Earnings of USD -3.04 million. Gross margins narrowed from 23.73% to -193.15% compared to the same period last year, operating (EBITDA) margins now 32.66% from -571.71%. Change in operating ... Read more (Read more...)

  • CNW Group3 months ago

    Aytu BioScience to Webcast, Live, at VirtualInvestorConferences.com on October 5th

    Aytu BioScience to Webcast, Live, at VirtualInvestorConferences.com on October 5th

  • Aytu BioScience to Webcast, Live, at VirtualInvestorConferences.com on October 5th
    PR Newswire3 months ago

    Aytu BioScience to Webcast, Live, at VirtualInvestorConferences.com on October 5th

    ENGLEWOOD, Colo., Sept. 28, 2017 /PRNewswire/ -- Aytu BioScience (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that Josh Disbrow, Chief Executive Officer, will present live at VirtualInvestorConferences.com on October 5, 2017. This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days. During August 2017 Aytu BioScience announced an $11.8 million private placement to expand commercialization of the company's lead product Natesto®.

  • Aytu BioScience Common Stock Resumes Trading under Symbol 'AYTU' Today
    PR Newswire3 months ago

    Aytu BioScience Common Stock Resumes Trading under Symbol 'AYTU' Today

    ENGLEWOOD, Colo., Sept. 28, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that its permanent trading symbol of 'AYTU' has resumed trading and is reflective of the previously enacted stock split.

  • Aytu BioScience Announces Split-Adjusted Trading of its Common Stock
    PR Newswire4 months ago

    Aytu BioScience Announces Split-Adjusted Trading of its Common Stock

    ENGLEWOOD, Colo. , Aug. 29, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today ...

  • Aytu BioScience Announces Reverse Split of its Common Stock
    PR Newswire4 months ago

    Aytu BioScience Announces Reverse Split of its Common Stock

    ENGLEWOOD, Colo., Aug. 25, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that a previously approved 1-for-20 reverse split of its outstanding shares of common stock is effective as of today, August 25, 2017.  The company anticipates announcement of the reverse split on the FINRA Daily List on Monday, August 28, 2017, with trading to commence on a post-split basis on Tuesday, August 29, 2017. The reverse stock split was approved by stockholders of Aytu at the Special Shareholders meeting held on July 26, 2017 and the ratio of 1-for-20 was authorized by the Board of Directors.  The stock split is intended to increase the per share trading price of the Company's common stock to enable the Company to satisfy the minimum bid price requirement for a planned listing on a national exchange.

  • Aytu BioScience to Provide Fiscal Fourth Quarter and Year-End 2017 Business Update
    PR Newswire4 months ago

    Aytu BioScience to Provide Fiscal Fourth Quarter and Year-End 2017 Business Update

    ENGLEWOOD, Colo., Aug. 24, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced that the Company will present its operational results for the fourth quarter and fiscal year-end 2017 on Thursday, August 31, 2017, at 10:30 a.m. ET.  The Company will review recent accomplishments and provide an overview of its business and growth strategy, as well as its financial results for the fiscal fourth quarter and year ended June 30, 2017. The webcast will be accessible live and archived on Aytu BioScience's website, within the Investors section under Corporate Presentations & Media, at aytubio.com, for 90 days. Aytu BioScience is a commercial-stage specialty life sciences company focused on global commercialization of novel products in the field of urology, with a focus on products addressing vitality, sexual wellness, and reproductive health.

  • Aytu BioScience, Inc. Announces Closing of $11.8 Million Private Placement
    PR Newswire4 months ago

    Aytu BioScience, Inc. Announces Closing of $11.8 Million Private Placement

    ENGLEWOOD, Colo., Aug. 15, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU) a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced the closing, on August 15, 2017, of its previously disclosed private placement of equity units, which resulted in gross proceeds of $11.8 million, before deducting placement agents' fees and estimated offering expenses. Aytu BioScience has agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock, including shares of common stock issuable upon exercise of the warrants, to be issued in the private placement.

  • Aytu BioScience, Inc. Announces $11.5 Million Private Placement
    PR Newswire4 months ago

    Aytu BioScience, Inc. Announces $11.5 Million Private Placement

    ENGLEWOOD, Colo., Aug. 11, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (AYTU) a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced that it has received subscriptions for a private placement in the amount of approximately $11.5 million of equity units. Class A units consist of one (1) share of common stock and a warrant to purchase one and one-half (1.5) shares of common stock and were sold at a negotiated price of $0.15 per unit. Class B units consist of one (1) share of Series A Preferred Stock and warrants to purchase one and one-half (1.5) shares of common stock for each share of common stock into which the Series A Preferred Stock is convertible and were sold at a negotiated price of $1,000 per unit to those purchasers who, together with their affiliates and certain related parties, would beneficially own more than 9.99% of the Company's outstanding common stock following the offering.

  • Aytu BioScience Expands MiOXSYS® Distribution Network with a Fertility-Focused Company in Over 20 Countries in Europe
    PR Newswire5 months ago

    Aytu BioScience Expands MiOXSYS® Distribution Network with a Fertility-Focused Company in Over 20 Countries in Europe

    ENGLEWOOD, Colo. , July 13, 2017 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today ...